Kinsale Capital Group, Inc.
KNSL
$367.16
-3.17%
Kinsale Capital Group, Inc. is a specialty insurance holding company operating exclusively in the excess and surplus (E&S) lines market, offering property, casualty, and specialty insurance products across niches such as allied health, healthcare, life sciences, and public entities. The company has carved out a distinct competitive identity as a low-cost, technology-driven E&S insurer, consistently delivering superior underwriting margins and organic growth in a fragmented market. Currently, the investor narrative centers on the stock's sharp recovery from a 52-week low, driven by robust earnings growth and a favorable pricing environment, while debates persist about valuation sustainability and competitive pressures in the E&S cycle.…
KNSL
Kinsale Capital Group, Inc.
$367.16
Investment Opinion: Should I buy KNSL Today?
Based on the analysis, Kinsale Capital is rated a Buy. The company's strong revenue growth, high profitability, and attractive valuation relative to growth (PEG 0.84) support a positive outlook. The average analyst target of $349.78 implies a potential downside of 7.8% from the current price of $379.19, but the high target of $405 suggests upside of 6.8%. The consensus recommendation is mixed, with recent downgrades, but the fundamentals remain robust.
Sign up to view all
KNSL 12-Month Price Forecast
The AI assessment leans bullish due to Kinsale's strong fundamentals and attractive valuation. However, the medium confidence reflects the mixed analyst sentiment and potential for growth deceleration. If the company can sustain revenue growth above 10% and maintain margins, the stock is likely to appreciate. Key developments to watch include quarterly earnings, E&S pricing trends, and any changes in analyst recommendations.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Kinsale Capital Group, Inc.'s 12-month outlook, with a consensus price target around $349.78 and implied upside of -4.7% versus the current price.
Average Target
$349.78
0 analysts
Implied Upside
-4.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$259 - $405
Analyst target range
The target price range spans from a low of $259.00 to a high of $405.00, indicating a wide dispersion of 56.4% from low to high, which reflects significant uncertainty about the company's future. The high target of $405 assumes continued strong underwriting margins and growth, while the low target of $259 prices in potential margin compression or a cyclical downturn in the E&S market. Recent rating actions show a mixed trend, with Wells Fargo downgrading from Overweight to Equal Weight in April 2026 and Jefferies downgrading to Underperform in March 2026, while Truist maintains a Buy. This pattern suggests that analysts are becoming more cautious, which could weigh on the stock's near-term performance.
Bulls vs Bears: KNSL Investment Factors
Kinsale Capital presents a compelling bull case with strong revenue growth, high profitability, and an attractive PEG ratio, but the bear case highlights valuation concerns, analyst downgrades, and moderating growth. Currently, the bull case has stronger evidence due to the company's exceptional underwriting performance and low-cost advantage, which justify a premium valuation. The most critical tension is whether the deceleration in growth is a temporary cyclical slowdown or a structural shift, as this will determine if the stock can sustain its current valuation or face multiple compression.
Bullish
- Strong Revenue Growth: Q1 2026 revenue grew 10.2% YoY to $466.7M, with a consistent upward trend from $423.4M in Q1 2025 to $497.5M in Q3 2025. This demonstrates robust demand in the E&S market, supporting continued earnings expansion.
- High Profitability Metrics: Net margin stands at 26.9%, operating margin at 33.8%, and ROE at 25.7%. These are exceptional for the insurance sector, reflecting Kinsale's low-cost structure and disciplined underwriting.
- Attractive Valuation with PEG: Trailing PE is 17.97x and forward PE is 17.52x, with a PEG ratio of 0.84, suggesting the stock is undervalued relative to its growth prospects. The low forward PE implies modest EPS growth expectations, which could be conservative given historical performance.
- Strong Free Cash Flow: Free cash flow TTM is $1.01B, providing ample capital for growth initiatives and potential shareholder returns. This financial flexibility supports the company's ability to navigate market cycles.
Bearish
- Significant Drawdown Risk: The stock experienced a max drawdown of -40.76% over the past year, highlighting its volatility. Despite the recovery, the stock remains 21.8% below its 52-week high of $485.00, suggesting potential resistance and lingering bearish sentiment.
- Analyst Downgrades: Wells Fargo downgraded from Overweight to Equal Weight in April 2026, and Jefferies downgraded to Underperform in March 2026. These actions reflect growing caution among analysts about the stock's valuation and future growth prospects.
- Moderating Growth: Revenue growth decelerated from 18% in 2024 to 10.2% in Q1 2026. This slowdown, while typical as the market matures, could lead to lower earnings growth and pressure the stock's premium valuation.
- High Valuation Relative to Peers: With a PS ratio of 4.83x and PB ratio of 4.62x, Kinsale trades at a premium to many insurance peers. If the market re-rates the stock to more typical levels, the downside could be significant.
KNSL Technical Analysis
Kinsale's stock has been in a pronounced recovery phase, with the current price of $379.19 representing a 16.4% decline over the past year but a strong rebound from its 52-week low of $287.20. The stock is trading at 78.2% of its 52-week range (between $287.20 and $485.00), indicating it has recovered significantly from the lows but remains well below its highs. This positioning suggests a mix of renewed investor confidence and lingering caution, as the stock has yet to reclaim its previous peak, implying potential resistance overhead.
Beta
0.89
0.89x market volatility
Max Drawdown
-40.8%
Largest decline past year
52-Week Range
$287-$485
Price range past year
Annual Return
-16.9%
Cumulative gain past year
| Period | KNSL Return | S&P 500 |
|---|---|---|
| 1m | +6.7% | +4.0% |
| 3m | +17.1% | +5.3% |
| 6m | -3.3% | +12.6% |
| 1y | -16.9% | +20.1% |
| ytd | -6.4% | +13.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
KNSL Fundamental Analysis
Kinsale's revenue trajectory remains robust, with Q1 2026 revenue of $466.7 million, up 10.2% year-over-year, and a consistent upward trend from $423.4 million in Q1 2025 to $497.5 million in Q3 2025. The company's growth is driven by strong premium retention and rate increases in the E&S market, though the pace has moderated from the 18% growth seen in 2024. This deceleration is typical as the market matures, but the absolute growth remains impressive for a specialty insurer, supporting the investment case for continued earnings expansion.
Quarterly Revenue
$466709000.0B
2026-03
Revenue YoY Growth
+10.2%
YoY Comparison
Gross Margin
39.9%
Latest Quarter
Free Cash Flow
$1.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is KNSL Overvalued?
Given Kinsale's positive net income, the PE ratio is the primary valuation metric, with a trailing PE of 17.97x and a forward PE of 17.52x, indicating the market expects stable earnings growth. The gap between trailing and forward PE is minimal, suggesting that analysts anticipate modest EPS growth of approximately 2.5% over the next year, which is conservative given the company's historical growth rates. This low forward PE relative to growth may signal that the stock is undervalued if the company can sustain its underwriting performance.
PE
18.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 16x~44x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Kinsale's financial health is solid, with a debt-to-equity ratio of only 0.11, indicating minimal leverage. However, the company's reliance on continued premium growth is a risk; if the E&S market softens, revenue growth could decelerate faster than expected. The net margin of 26.9% is high but could be pressured by rising loss costs or competitive pricing. Additionally, the payout ratio is only 3.1%, so dividend increases are unlikely to attract income investors, but the low payout provides flexibility for reinvestment.
FAQ
The key risks include: (1) Financial risk: reliance on continued premium growth; if the E&S market softens, revenue growth could decelerate. (2) Market risk: the stock is volatile, with a beta of 0.89 and a max drawdown of -40.76%, so investors could face significant losses. (3) Competitive risk: increased competition in the E&S market could pressure margins. (4) Company-specific risk: recent analyst downgrades may signal deteriorating sentiment. The most severe risk is a cyclical downturn in the E&S market, which could lead to a decline toward the 52-week low of $287.20.
The 12-month forecast is mixed. The bull case (30% probability) targets $405-$485, driven by strong growth and favorable market conditions. The base case (50% probability) targets $350-$405, assuming continued moderate growth. The bear case (20% probability) targets $259-$287, if the market deteriorates. The most likely scenario is the base case, with the stock trading around the analyst average target of $349.78. Key assumptions include revenue growth of 8-10% and stable margins.
Kinsale's valuation is mixed. On a PE basis, it trades at 17.97x trailing and 17.52x forward, which is below the market average but above some insurance peers. The PEG ratio of 0.84 suggests it is undervalued relative to its growth rate. However, the PS ratio of 4.83x and PB ratio of 4.62x are high, indicating the market is paying a premium for its profitability. Overall, the stock appears fairly valued to slightly undervalued, with the market pricing in modest growth expectations.
Kinsale Capital is a good buy for investors seeking a high-quality growth stock with a reasonable valuation. The stock trades at a forward PE of 17.5x, which is attractive given its historical growth and profitability. The average analyst target of $349.78 implies a modest downside, but the high target of $405 suggests upside potential. However, the stock is not without risks, including potential margin compression and market volatility. For long-term investors with a tolerance for drawdowns, KNSL offers a compelling risk/reward profile.
Kinsale is better suited for long-term investment due to its strong fundamentals and growth potential. The stock has a beta of 0.89, indicating lower volatility than the market, but it has experienced significant drawdowns, making it unsuitable for short-term trading. The company's low dividend yield (0.17%) means income is not a primary reason to hold. For long-term investors, a minimum holding period of 3-5 years is recommended to ride out market cycles and benefit from earnings growth.